Naibec Announces COVID-19 Treatment NIPEP-ACOV at American Society for Immunology and Infection Meeting

[Asia Economy Reporter Hyunseok Yoo] Peptide fusion bio company Nivek has been invited to the American Society for Immunology and Infectious Diseases to present its research achievements on the novel coronavirus disease (COVID-19) treatment to global big pharma and key stakeholders worldwide.

Nivek announced on the 16th that it has been invited to the American Society for Immunology and Infectious Diseases to present the research results of the COVID-19 treatment NIPEP-ACOV and plans to promote corporate partnering meetings with global pharmaceutical companies and global investors.

The American Society for Immunology and Infectious Diseases is the 'Infectious Immunity Conference' hosted by MedInvest, held over three days from the 15th to the 17th of this month. Two days are dedicated to corporate presentations, and one day is for corporate partnering meetings.

This conference includes participation from 35 pharmaceutical and life science companies researching COVID-19 treatments, discussing recent research trends and clinical progress in COVID-19 diagnostics, therapeutics, and preventive vaccines.

The COVID-19 treatment 'NIPEP-ACOV' that Nivek will present has been confirmed to not only have antiviral effects but also to reduce the main factors causing cytokine storms by more than 90%, and preliminary toxicity tests have already been completed to verify its safety.

Following the '2020 BIO International Convention BIO USA,' Nivek plans to actively conduct research on COVID-19 treatments through domestic and international consortia, including the United States and Europe, by presenting the current status of its COVID-19 treatment research at this Infectious Immunity Conference.

A Nivek representative said, “Following our participation in BIO USA, being invited to this Immunology and Infectious Diseases Society allowed us to present our COVID-19 treatment research achievements and hold meetings with various global pharmaceutical and biotechnology companies, reaffirming the originality and efficacy of Nivek’s NIPEP-ACOV.”

He added, “Through participation and presentations at the conference, we discussed further clinical progress. We plan to accelerate research not only in Europe and the United States, where studies are currently underway, but also domestically, to advance preclinical research and clinical trials.”

This content was produced with the assistance of AI translation services.